Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 17, 2021 2:04pm
155 Views
Post# 34137277

RE:RE:Another Target Expression Comparison: Trop-2

RE:RE:Another Target Expression Comparison: Trop-2It is in the fourth section (Discussion) in their paper published in Cancer Science May 2021.  It's the second to last paragraph in the whole paper.  They mention that Sort1 was "upregulated" in around 60% of TNBC subtypes while PD-1 was upregulated in only 19% of TNBC.  THTX's 60% in TNBC is from the paper by Roselli & Pundavela (Oncotarget 2015, Sortilin is assoc with breast cancer aggresiveness...".  The PD-1 stat is from Sun, Lee "Expression of PD-L1 in TNBC based on different immunohitochemical antibodies. J Transl Med 2016.

Love it if you can find more definitive stats like that around other tumor types and other targets being used for cancer treatements. 

jfm1330 wrote: Where did Thera release that info?



Wino115 wrote: So we learned from THTX that sortilin overexpression is 3x that of PD-1 (Keytruda's target) in tumors.  




<< Previous
Bullboard Posts
Next >>